Delisting riskPopularity #4,715
MSLE · NASDAQ · Biotechnology

Satellos Bioscience (MSLE)

Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.

$9.02
After hours+0.02 (+0.20%)
At close$9.00(−1.96%)

Something off on this page? Send us feedback.

Next report
Nov 13, 26
estimated · in 52 days
EPS estimate
−$0.58
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.50−$0.47−$0.36−$0.36−$0.47−$0.53−$0.56Pending
Estimate−$0.34−$0.38−$0.27−$0.33−$0.36−$0.51−$0.38−$0.58
Surprise−45.5%−23.5%−35.5%−11.1%−30.6%−3.9%−47.4%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2030−$0.12
Sep 2030−$0.41
Jun 2030−$0.57
Mar 2030−$0.88
Dec 2029−$0.73
Sep 2029−$0.79
Jun 2029−$0.71
Mar 2029−$0.63
Dec 2028−$0.62
Sep 2028−$0.54
Jun 2028−$0.53
Mar 2028−$0.58
Dec 2027−$0.67
Sep 2027−$0.65
Jun 2027−$0.61
Mar 2027−$0.63
Dec 2026−$0.60
Nov 2026−$0.58
Aug 2026−$0.38−$0.56−47.4%
May 2026−$0.51−$0.53−3.9%
Mar 2026−$0.36−$0.47−30.6%
Nov 2025−$0.33−$0.36−11.1%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024

The latest year is open to everyone — the 7 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2030−$0.12$0
Sep 2030−$0.41$0
Jun 2030−$0.57$0
Mar 2030−$0.88$0
Dec 2029−$0.73$0
Sep 2029−$0.79$0
Jun 2029−$0.71$0
Mar 2029−$0.63$0
Dec 2028−$0.62$0
Sep 2028−$0.54$0
Jun 2028−$0.53$0
Mar 2028−$0.58$0
Dec 2027−$0.67$0
Sep 2027−$0.65$0
Jun 2027−$0.61$0
Mar 2027−$0.63$0
Dec 2026−$0.60$0
Nov 13, 2026−$0.58$0
Aug 13, 2026−$0.38−$0.56−47.4%−2.0%
May 14, 2026−$0.51−$0.53−3.9%−1.5%
Mar 27, 2026−$0.36−$0.47−30.6%−10.7%
Nov 14, 2025−$0.33−$0.36−11.1%
Aug 13, 2025
May 13, 2025
Mar 26, 2025
Nov 13, 2024
Aug 12, 2024
May 14, 2024
Mar 27, 2024

The latest year is open to everyone — the 7 quarters behind it read with an account.